
Brief intro:
- Author: Ting Lan, Huangyao Chen, Chengcheng Tang, Yuhui Wei, Yang Liu, Jizeng Zhou, Zhenpeng Zhuang, Quanjun Zhang, Min Chen, Xiaoqing Zhou, Yue Chi, Jinling Wang, Yu He, Liangxue Lai, and Qingjian Zou
- Journal: Mol Ther Nucleic Acids
- Doi: https://www.doi.org/10.1016/j.omtn.2023.08.018
- Publication Date: 2023 Aug 17
Products/Services used in the paper
Quotation shows PackGene:AAV9 was packaged by PackGene Biotech Co., Ltd.
Research Field:gene editing; eye
AAV Serotype:AAV9
Targeted organ:eye
Animal or cell line strain:the two-week-old mice
Abstract
Prime editor (PE) is a versatile genome-editing tool without needing extra DNA donors or inducing double-strand breaks. However, in vivo implementation of PE remains challenge because of its oversized composition. In this study, we screened out the smallest truncated Moloney-murine leukemia virus reverse transcriptase (M-MLV RT) with F155Y mutation to keep gene editing efficiency. The truncated M-MLV RT variant was further fused with Campylobacter jejuni Cas9 (CjCas9, H559A) to construct a mini-PE system with a reduced gene size (4.5 kb) right in the packaging capacity of adeno-associated virus. After optimizing of the pegRNAs and incorporating with nick sgRNAs, the mini-PE delivered up to 10% precise editing at target sites in human and mouse cells. It also edited mouse Hsf1 gene in mouse retina precisely after delivered with AAVs, although the editing efficiency was lower than 1%. We will focus on improving the editing efficiency of mini-PE, and exploiting it therapeutic potential against human genetic diseases.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
